Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia

European Journal of Dermatology

Volumn 18, Issue 6, 2008, Pages 717-718

  Schierl, Michael ^a   Foedinger, Dagmar ^b   Geissler, Klaus ^c,d   Rappersberger, Klemens ^e   Feldmann, Robert ^a  

^a Hietzing Hospital   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c 5th Department of Internal Medicine with Oncology   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^e KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DESMOGLEIN 3 ANTIBODY; FLUDARABINE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONJUNCTIVITIS; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INFLAMMATORY INFILTRATE; MAINTENANCE THERAPY; MALE; PARANEOPLASTIC PEMPHIGUS; RASH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; PEMPHIGUS; VIDARABINE;

EID: 57749179029     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0528     Document Type: Article

References (7)

1. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H 3rd, Mutasim D, Ariss-Abdo L, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323(25): 1729-35.
2. Gooptu C, Littlewood TJ, Frith P, Lyon CC, Carmichael AJ, Oliwiecki S, MacWhannell A, Amagai M, Hashimoto T, Dean D, Allen J, Wojnarowska F. Paraneoplastic pemphigus: an association with fludarabine? Br J Dermatol 2001; 144: 1255-61.
3. Bazarbachi A, Bachelez H, Dehen L, et al. Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukoemia with fludarabine. Ann Oncol 1995; 6: 730-1.
4. Powell AM, Albert S, Oyama N, Sakuma-Oyama Y, Bhogal B, Black MM. Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral emphigus vegetans. J Eur Acad Dermatol Venereol 2004; 18(3): 360-4.
5. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-52.
6. Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther 2007; 20(4): 277-87.
7. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6(5): 366-73.